Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  75 results for ""GLUCAGON-like peptide-1 agonists""

Your Filters

Publication : lancet Filter by : Subject
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.

Subjects: Glucagon-like peptide-1 agonists; Sodium-glucose cotransporter 2 inhibitors; Cardiovascular diseases

  • Source: Lancet. Jul2021, Vol. 398 Issue 10296, p262-276. 15p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Subjects: *Research; *Self-evaluation; Type 2 diabetesMexico; India; JapanEli Lilly & Co. Eli Lilly & Co. Eli Lilly & Co. LLY

  • Source: Lancet. Jul2021, Vol. 398 Issue 10295, p143-155. 13p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.

Subjects: RANDOMIZED controlled trials; DRUG therapy; WEIGHT loss

  • Source: Lancet. Jan2022, Vol. 399 Issue 10321, p259-269. 11p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?

Subjects: Glucagon-like peptide-1 receptor; Glucagon-like peptide-1 agonists; Type 2 diabetes

  • Source: Lancet. Jul2019, Vol. 394 Issue 10192, p4-6. 3p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.

Subjects: Glucagon-like peptide-1 agonists; Chemical agonists; Overweight persons

  • Source: Lancet. 6/30/2018, Vol. 391 Issue 10140, p2607-2618. 12p. 3 Charts, 1 Graph.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

Subjects: TYPE 2 diabetes; GLOMERULAR filtration rate; GLUCAGON-like peptide-1 agonists

  • Source: Lancet. Jul2019, Vol. 394 Issue 10193, p131-138. 8p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.

Subjects: NOVO Nordisk A/S; TYPE 2 diabetes; CLINICAL trial registries

  • Source: Lancet. Jul2019, Vol. 394 Issue 10192, p39-50. 12p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Technology to overcome clinical inertia in insulin therapy.

Subjects: INSULIN; TECHNOLOGY; GLUCOSE analysis

  • Source: Lancet. 3/16/2019, Vol. 393 Issue 10176, p1078-1080. 3p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

Liraglutide for patients with non-alcoholic steatohepatitis.

Subjects: Glucagon-like peptide-1 agonists; Fatty liver; Drug efficacy

  • Source: Lancet. 6/11/2016, Vol. 387 Issue 10036, p2378-2379. 2p.

Record details

Read Online More Details Get Citations Add to Saved list
×
Academic Journal

GLP-1 receptor agonists and basal insulin in type 2 diabetes.

Subjects: *Cost effectiveness; Glucagon-like peptide-1 agonists; Insulin therapy

  • Source: Lancet. 12/20/2014, Vol. 384 Issue 9961, p2180-2181. 2p.

Record details

Read Online More Details Get Citations Add to Saved list
×
  • 1-10 of  75 results for ""GLUCAGON-like peptide-1 agonists""